All Clinical Trials

Clinical Trial

ACNS1422, A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-RiskWNT-Driven Medulloblastoma Patients

  • Recruiting participants (Starts Nov. 1, 2017)
  • Not accepting healthy volunteers
  • UTSW Principal Investigator: Daniel C Bowers

summary

Primary: To estimate the progression-free survival (PFS) of children >= 3 years of age with WNT-driven average-risk medulloblastoma using reduced craniospinal radiotherapy (CSI) (18 Gy) with a limited target volume boost to the tumor bed of 36 Gy for a tot

If you are interested in this clinical trial, please contact Brittany Glass-Thomas on the Children’s Health Research Team.Call 214-456-4182Email